Lupin Limited's US subsidiary, Lupin Pharmaceuticals, has received tentative approval from the US Food and Drugs Administration for its Pregabalin Capsules, the company said in a statement to the Bombay Stock Exchange.
Pregabalin Capsules are AB-rated generic equivalent of company's Lyrica capsules indicated for neuropathic pain associated with diabeties, post herpetic neuralgia and adjunctive therapy for adult patients.
Lyrica capsules are available in 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg and had annual US sales of around $1.7 billion for the twelve months ending March 2011, the company statement added.
Lupin's scrip was up 2.20 per cent at Rs 460.15 on the Bombay Stock Exchange.
